Tuesday - April 22, 2025

LOGIN  |  REGISTER
C4 Therapeutics

Syra Health To Discuss Fourth Quarter and Fiscal Year 2023 Financial Results

March 19, 2024 | Last Trade: US$0.10 0.00 0.00
  • Conference call will be held on Monday, March 25 at 9:00 a.m. ET

CARMEL, Ind., March 19, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare consulting company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it will report financial results for its fourth quarter and fiscal year 2023 ended December 31, 2023, on Monday, March 25, 2024, before the market opens. The Company has scheduled a conference call for that same day, March 25, 2024, at 9:00 a.m. ET, to review the results.

Interested parties can access the conference call via Internet webcast, which is available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2023-earnings-call.

Investors who would like to submit a question to be addressed on the call should email the question to shamsian@lythampartners.com.

A webcast replay will be available in the Investors section of the Company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2023-earnings-call.

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental healthdigital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.

For more information, please contact:

For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
christined@syrahealth.com

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
shamsian@lythampartners.com

Terns Pharmaceuticals

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page